
NASDAQHealthcareMedical - Devices
Latest quote
$16.72
+$0.28 · +1.70%
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.
Previous close
$16.72
+$0.28 · +1.70%
Regular session · ET · Market data may be delayed.
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.
Day range
Current $16.72
52-week range
Current $16.72
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
63
Undervalued
Sentiment
64
Bullish
Risk
41
Elevated Risk
Momentum
70
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.
Day range
Current $16.72
52-week range
Current $16.72
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.64B USD | 1.61B USD | 1.54B USD | 1.56B USD | 1.54B USD |
| Cost of goods sold | 790.01M USD | 728.47M USD | 656.84M USD | 587.36M USD | 597.81M USD |
| Gross profit | 845.23M USD | 882.06M USD | 884.74M USD | 970.31M USD | 944.64M USD |
| Research and development | 98.97M USD | 115.38M USD | 104.19M USD | 101.19M USD | 93.05M USD |
| Selling, general, and administrative | 699.7M USD | 716.98M USD | 656.64M USD | 616.32M USD | 637.45M USD |
| Operating expenses | 776.92M USD | 853.65M USD | 773.21M USD | 731.39M USD | 747.41M USD |
| Interest income | 18.47M USD | 20.04M USD | 17.2M USD | 11.92M USD | 6.74M USD |
| Interest expense | 86.26M USD | 70.63M USD | 51.38M USD | 49.59M USD | 50.4M USD |
| Depreciation and amortization | 151.05M USD | 140.5M USD | 123.51M USD | 121.12M USD | 123.67M USD |
| Operating income | 68.32M USD | 28.41M USD | 111.53M USD | 238.92M USD | 197.23M USD |
| Net income | −516.47M USD | −6.94M USD | 67.74M USD | 180.55M USD | 169.08M USD |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$20.50
22.61% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 4, 2017 | 2:1 | — | — |
Stock split | Jul 1, 2015 | 553:500 | — | — |
Stock split | May 26, 1998 | 1:2 | — | — |
Effective Jan 4, 2017
2:1
Effective Jul 1, 2015
553:500
Effective May 26, 1998
1:2
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR71.93M0.06%109.08B USD0.06%$145.34+0.37%
Vanguard Morningstar Total Stock Market ETFVTI35.1M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM29.14M0.04%79.88B USD0.19%$296.01+0.28%
Vanguard Morningstar Small-Cap ETFVB25.3M0.01%183.4B USD0.03%$300.01+0.05%
Vanguard Morningstar Small-Cap Value ETFVBR16.08M0.02%68.3B USD0.05%$247.11+0.08%
Vanguard Extended Market ETFVXF12.84M0.01%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Value ETFIWN10.62M0.07%14.47B USD0.24%$224.62+0.40%
iShares S&P Small-Cap 600 Value ETFIJS10.57M0.13%8.24B USD0.18%$137.54+0.63%
iShares Core S&P Small-Cap ETFIJR
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Value ETFVBR
Vanguard Extended Market ETFVXF
iShares Russell 2000 Value ETFIWN
iShares S&P Small-Cap 600 Value ETFIJSAI-generated and delayed market data for informational and educational purposes only. Not investment advice.